{"id":"praluent-alirocumab","safety":{"commonSideEffects":[{"rate":"3-5","effect":"Injection site reactions"},{"rate":"5-7","effect":"Nasopharyngitis"},{"rate":"2-4","effect":"Influenza"},{"rate":"2-3","effect":"Myalgia"},{"rate":"2-3","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PCSK9 normally binds to LDL receptors on hepatocytes and promotes their degradation, reducing the liver's ability to clear LDL cholesterol from the blood. By blocking PCSK9, alirocumab prevents this degradation, allowing more LDL receptors to remain on the cell surface and increasing LDL cholesterol uptake from circulation. This results in significant reductions in plasma LDL cholesterol levels.","oneSentence":"Alirocumab is a monoclonal antibody that binds to and inhibits PCSK9, a protein that degrades LDL receptors, thereby increasing LDL receptor availability and lowering blood LDL cholesterol.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:02:03.807Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia (heterozygous familial and non-familial) in patients not adequately controlled by statins"},{"name":"Homozygous familial hypercholesterolemia"},{"name":"Established cardiovascular disease (secondary prevention)"}]},"trialDetails":[{"nctId":"NCT04862260","phase":"EARLY_PHASE1","title":"Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"CHU de Quebec-Universite Laval","startDate":"2021-10-04","conditions":"Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreas Cancer","enrollment":3},{"nctId":"NCT07477704","phase":"PHASE2","title":"A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia","status":"NOT_YET_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-04-14","conditions":"Hypercholesterolemia","enrollment":420},{"nctId":"NCT03537742","phase":"PHASE2","title":"Cardiac Allograft Vasculopathy Inhibition With Alirocumab","status":"COMPLETED","sponsor":"Stanford University","startDate":"2019-05-13","conditions":"Vasculopathy","enrollment":114},{"nctId":"NCT06385262","phase":"PHASE2","title":"TOP 2301: Neoadjuvant Chemo for NSCLC","status":"SUSPENDED","sponsor":"Duke University","startDate":"2025-03-17","conditions":"Non Small Cell Lung Cancer","enrollment":126},{"nctId":"NCT07375225","phase":"","title":"Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy","status":"RECRUITING","sponsor":"Federico II University","startDate":"2024-12-01","conditions":"Hypercholesterolaemia","enrollment":1500},{"nctId":"NCT05292404","phase":"PHASE4","title":"Impact of Early PCSK9 Inhibitor Treatment on Heart After Acute Myocardium Infarction","status":"RECRUITING","sponsor":"Shanghai Tong Ren Hospital","startDate":"2022-10-01","conditions":"Acute Myocardial Infarction","enrollment":160},{"nctId":"NCT05553834","phase":"PHASE2","title":"PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung","status":"ACTIVE_NOT_RECRUITING","sponsor":"Duke University","startDate":"2023-05-16","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":60},{"nctId":"NCT05430828","phase":"","title":"Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy","status":"RECRUITING","sponsor":"Federico II University","startDate":"2020-03-07","conditions":"Hypercholesterolemia","enrollment":5000},{"nctId":"NCT04781322","phase":"PHASE1","title":"Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers","status":"RECRUITING","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2021-10-19","conditions":"Alcohol Associated Liver Disease, Heavy Drinking Behavior","enrollment":100},{"nctId":"NCT03207945","phase":"PHASE3","title":"Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2018-04-30","conditions":"Dyslipidemias, Cardiovascular Diseases, HIV Infections","enrollment":118},{"nctId":"NCT06791031","phase":"NA","title":"PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in Acute Coronary Syndromes (REPRESS)","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-01","conditions":"Coronary Artery Disease","enrollment":212},{"nctId":"NCT07174375","phase":"PHASE2, PHASE3","title":"PCSK9 Inhibitors in Acute Ischemic Stroke Patients Undergoing Endovascular Therapy","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-09-15","conditions":"Acute Ischemic Stroke","enrollment":478},{"nctId":"NCT06858332","phase":"","title":"Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-04-15","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":2382},{"nctId":"NCT07023445","phase":"","title":"Patterns of Inclisiran Use in the Real World: An Analysis of US Databases","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-01-20","conditions":"Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia","enrollment":37688},{"nctId":"NCT04731155","phase":"PHASE4","title":"Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction","status":"RECRUITING","sponsor":"Shanghai Tong Ren Hospital","startDate":"2021-04-12","conditions":"Early PCSK9 Inhibitor on Ventricular Remodling","enrollment":20},{"nctId":"NCT03110432","phase":"","title":"Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry","status":"COMPLETED","sponsor":"GWT-TUD GmbH","startDate":"2017-05-18","conditions":"Dyslipoproteinemias, Hypercholesterolemia, Familial, Familial Hypercholesterolemia - Homozygous","enrollment":1695},{"nctId":"NCT05001984","phase":"PHASE2","title":"Trial of PCSK9 Inhibition in Patients with Acute Stroke and Symptomatic Intracranial Atherosclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2021-08-01","conditions":"Intracranial Atherosclerosis, Acute Ischemic Stroke, ICAS - Intracranial Atherosclerosis","enrollment":60},{"nctId":"NCT05469347","phase":"PHASE1","title":"Alirocumab in Patients with Sepsis","status":"COMPLETED","sponsor":"Jonathan Sevransky","startDate":"2023-01-04","conditions":"Sepsis","enrollment":50},{"nctId":"NCT05129241","phase":"","title":"Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-11-18","conditions":"Primary Hypercholesterolaemia and Mixed Dyslipidaemia, Atherosclerotic Cardiovascular Disease","enrollment":163},{"nctId":"NCT06738758","phase":"","title":"Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients(ELITE-ACS)","status":"RECRUITING","sponsor":"Yun Dai Chen","startDate":"2024-12-16","conditions":"Acute Coronary Syndromes","enrollment":6000},{"nctId":"NCT05537948","phase":"PHASE4","title":"Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Medical Research Center for Therapy and Preventive Medicine","startDate":"2021-10-01","conditions":"Dyslipidemias, Hyperlipidemias, Liver Transplant Disorder","enrollment":59},{"nctId":"NCT04656028","phase":"NA","title":"Genetic Testing and Motivational Counseling for FH","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Medical Research Center for Therapy and Preventive Medicine","startDate":"2020-06-15","conditions":"Hypercholesterolemia, Familial, Hypercholesterolemia, Familial, 1, Hypercholesterolemia, Familial, 2","enrollment":180},{"nctId":"NCT06567418","phase":"","title":"Retrospective Analysis of the Effect of In-hospital Initiation of PCSK9i on Clinical Outcomes in Chinese ACS Patients","status":"RECRUITING","sponsor":"Yun Dai Chen","startDate":"2024-08-01","conditions":"Acute Coronary Syndrome","enrollment":10000},{"nctId":"NCT04847752","phase":"","title":"Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2021-03-01","conditions":"Ischemic Stroke, Large-Artery Atherosclerosis (Embolus/Thrombosis)","enrollment":1000},{"nctId":"NCT04968509","phase":"PHASE3","title":"Effect of PCSK9 Inhibitors on Calcific Aortic Valve Stenosis","status":"RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2024-03-22","conditions":"Aortic Stenosis","enrollment":160},{"nctId":"NCT06381947","phase":"PHASE4","title":"Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients","status":"NOT_YET_RECRUITING","sponsor":"University of Salerno","startDate":"2024-05-01","conditions":"Dyslipidemias, Statin Adverse Reaction, Cardiovascular Diseases","enrollment":130},{"nctId":"NCT04189484","phase":"PHASE1","title":"Pharmacodynamic Biomarkers to Support Biosimilar Development: PCSK9 Inhibitors","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2020-01-07","conditions":"Healthy Subjects, Pharmacokinetics, Pharmacodynamics","enrollment":72},{"nctId":"NCT05587621","phase":"NA","title":"Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target)","status":"NOT_YET_RECRUITING","sponsor":"Jena University Hospital","startDate":"2024-04-01","conditions":"ST Elevation Myocardial Infarction, Non-ST Elevation Myocardial Infarction, LDL-cholesterol","enrollment":300},{"nctId":"NCT06080256","phase":"PHASE3","title":"Extra Alirocumab in Addition to Statin Therapy in Asymptomatic Intracranial Atherosclerotic Stenosis (EAST-aICAS)","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-12-30","conditions":"Intracranial Atherosclerosis, Atherosclerotic Plaque, Stenosis","enrollment":80},{"nctId":"NCT05624658","phase":"NA","title":"Effect of Combined Lipid-lowering Therapy on Atherosclerotic Plaque Vulnerability in Patients With ACS","status":"UNKNOWN","sponsor":"Samara Regional Cardiology Dispensary","startDate":"2022-09-02","conditions":"Dyslipidemias","enrollment":200},{"nctId":"NCT06083961","phase":"PHASE4","title":"The Effect of Early Administration of PCSK9 Inhibitor to Acute Ischemic Stroke Patients Associated With Atherosclerosis on the Stroke Prognosis and Lipid Profile","status":"NOT_YET_RECRUITING","sponsor":"Sun U. Kwon","startDate":"2023-10-15","conditions":"Stroke, Acute Ischemic, PCSK9 Inhibitor","enrollment":200},{"nctId":"NCT04193306","phase":"PHASE4","title":"Efficacy and Safety Of Alirocumab to Prevent Early Cardiac Allograft Vasculopathy in Recent Heart Transplant Recipients","status":"UNKNOWN","sponsor":"Institute for Clinical and Experimental Medicine","startDate":"2019-11-18","conditions":"Cardiac Allograft Vasculopathy","enrollment":126},{"nctId":"NCT06052020","phase":"","title":"Extra Alirocumab in Addition to Statin Therapy in Symptomatic IntraCranial Atherosclerotic Stenosis ----a Pilot Study","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-09-15","conditions":"Stroke, Intracranial Atherosclerotic Stenosis","enrollment":50},{"nctId":"NCT03273972","phase":"NA","title":"INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2017-09-07","conditions":"Atherosclerosis, Cardiovascular Diseases","enrollment":30},{"nctId":"NCT02959047","phase":"PHASE4","title":"A Trial of Alirocumab and Plaque Regression in Peripheral Arterial Disease","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2017-07-17","conditions":"Peripheral Arterial Disease","enrollment":40},{"nctId":"NCT03510884","phase":"PHASE3","title":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-05-31","conditions":"Hypercholesterolaemia","enrollment":153},{"nctId":"NCT04790513","phase":"PHASE3","title":"Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients","status":"COMPLETED","sponsor":"LIB Therapeutics LLC","startDate":"2021-04-22","conditions":"Hypercholesterolemia, Cardiovascular Diseases","enrollment":204},{"nctId":"NCT03175367","phase":"PHASE2","title":"Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2017-11-10","conditions":"Hypercholesterolemia","enrollment":272},{"nctId":"NCT04319081","phase":"","title":"Study to Evaluate Changes in Cognitive Function in Patients Treated With PCSK9 Inhibitors","status":"COMPLETED","sponsor":"Jose Seijas Amigo","startDate":"2020-03-01","conditions":"Cognitive Function, Hypercholesterolemia, Quality of Life","enrollment":180},{"nctId":"NCT03344692","phase":"PHASE3","title":"Effect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2019-02-12","conditions":"Type2 Diabetes","enrollment":22},{"nctId":"NCT03004001","phase":"PHASE2","title":"Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome","status":"TERMINATED","sponsor":"Gloria Vega","startDate":"2017-01","conditions":"Nephrotic Syndrome","enrollment":3},{"nctId":"NCT05465278","phase":"PHASE4","title":"Alirocumab and Plaque Burden In Familial Hypercholesterolaemia","status":"COMPLETED","sponsor":"Fundación Hipercolesterolemia Familiar","startDate":"2018-05-01","conditions":"Familial Hypercholesterolemia","enrollment":104},{"nctId":"NCT03718286","phase":"PHASE2","title":"Effects of Acute, Rapid Lowering of LDL Cholesterol With Alirocumab in Patients With STEMI Undergoing Primary PCI","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2019-03-11","conditions":"ST Elevation Myocardial Infarction, Acute Coronary Syndrome, Hypercholesterolemia","enrollment":97},{"nctId":"NCT02476006","phase":"PHASE3","title":"Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-06-23","conditions":"Hypercholesterolemia","enrollment":998},{"nctId":"NCT03067844","phase":"PHASE3","title":"Vascular Effects of Alirocumab in Acute MI-Patients","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2017-04-25","conditions":"Coronary Vessel, Coronary Circulation, Atheroma; Myocardial","enrollment":294},{"nctId":"NCT05081336","phase":"","title":"Low-density Lipoprotein Cholesterol Reduction With State-of-the-art Therapy in Secondary Prevention and Major Cardiovascular Adverse Events: Republic of Srpska Registry","status":"UNKNOWN","sponsor":"University Clinical Centre of Republic of Srpska","startDate":"2021-03-01","conditions":"Acute Coronary Syndrome, Dyslipidemias","enrollment":500},{"nctId":"NCT03542110","phase":"PHASE4","title":"The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial","status":"TERMINATED","sponsor":"Minneapolis Heart Institute Foundation","startDate":"2018-08-04","conditions":"Saphenous Vein Graft Atherosclerosis","enrollment":46},{"nctId":"NCT05043740","phase":"NA","title":"PCSK9 Inhibitor on ACS Patients With Multivessel Disease and Relatively Low LDL-C Level in Chinese Population","status":"UNKNOWN","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2021-10","conditions":"Acute Coronary Syndrome","enrollment":1360},{"nctId":"NCT03355027","phase":"NA","title":"Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV Disease","status":"UNKNOWN","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2017-11-30","conditions":"Atherosclerosis, Cardiovascular Diseases","enrollment":60},{"nctId":"NCT03156621","phase":"PHASE3","title":"Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2017-10-03","conditions":"Homozygous Familial Hypercholesterolemia","enrollment":69},{"nctId":"NCT03694197","phase":"PHASE4","title":"Long Term Safety Study of PRALUENT","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2018-09-28","conditions":"Heterozygous Familial Hypercholesterolemia, Non-familial Hypercholesterolemia","enrollment":1389},{"nctId":"NCT02957682","phase":"PHASE4","title":"Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2016-11-02","conditions":"Hypercholesterolemia","enrollment":2176},{"nctId":"NCT04851769","phase":"PHASE4","title":"Impact of PCSK9 Inhibitors on Coronary Plaque Composition and Vulnerability Assessed by Optical Coherence Tomography","status":"COMPLETED","sponsor":"Beijing Anzhen Hospital","startDate":"2019-03-02","conditions":"Randomized Controlled Trials","enrollment":60},{"nctId":"NCT03510715","phase":"PHASE3","title":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-08-31","conditions":"Hypercholesterolemia","enrollment":18},{"nctId":"NCT03379558","phase":"","title":"Praluent® (Alirocumab) Pregnancy Exposure Registry: An OTIS Pregnancy Surveillance Study","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2017-12-19","conditions":"Hypercholesterolemia","enrollment":37},{"nctId":"NCT04613167","phase":"NA","title":"Markers of Cardiovascular Risk in Patients With Premature Coronary Artery Disease and Treatment","status":"UNKNOWN","sponsor":"University Medical Centre Ljubljana","startDate":"2020-11-10","conditions":"Acute Coronary Syndrome, Premature Coronary Heart Disease, Lipoproteinemia","enrollment":70},{"nctId":"NCT02941016","phase":"PHASE4","title":"Vascular Inflammation and Cholesterol Lowering Therapy","status":"WITHDRAWN","sponsor":"Rigshospitalet, Denmark","startDate":"2016-10","conditions":"Lipid Lowering, Vascular Inflammation","enrollment":""},{"nctId":"NCT01576484","phase":"PHASE2","title":"Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2012-02-28","conditions":"Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia","enrollment":58},{"nctId":"NCT01709513","phase":"PHASE3","title":"Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2012-09-30","conditions":"Hypercholesterolemia","enrollment":314},{"nctId":"NCT01604824","phase":"PHASE2","title":"A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2012-02-22","conditions":"Hypercholesterolemia","enrollment":23},{"nctId":"NCT02326220","phase":"PHASE3","title":"Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2015-03-31","conditions":"Heterozygous Familial Hypercholesterolemia","enrollment":62},{"nctId":"NCT03559309","phase":"PHASE4","title":"Investigating the Effects of Lipid-therapy Intensification With Alirocumab on Endothelial Function, Carotid Arteries, Lipoprotein Particle Subfractions, Inflammation and Post-prandial Lipemia","status":"TERMINATED","sponsor":"Medical University of Graz","startDate":"2018-06-20","conditions":"Atherosclerosis, Hypercholesterolemia, Post Prandial Lipemia","enrollment":24},{"nctId":"NCT03507374","phase":"EARLY_PHASE1","title":"PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis","status":"TERMINATED","sponsor":"University of Utah","startDate":"2018-10-30","conditions":"Stroke, Intracranial Atherosclerosis, Intraplaque Hemorrhage","enrollment":20},{"nctId":"NCT01730053","phase":"PHASE3","title":"Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2012-11-30","conditions":"Hypercholesterolemia","enrollment":305},{"nctId":"NCT03480568","phase":"PHASE3","title":"Alirocumab in Patients on a Stable Dialysis Regimen","status":"UNKNOWN","sponsor":"Baylor Research Institute","startDate":"2018-05-01","conditions":"Hemodialysis, Peritoneal Dialysis, Hypercholesterolemia","enrollment":20},{"nctId":"NCT02715726","phase":"PHASE3","title":"Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-27","conditions":"Hypercholesterolemia","enrollment":615},{"nctId":"NCT02984982","phase":"PHASE4","title":"Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-11-15","conditions":"Hypercholesterolemia, Acute Coronary Syndrome","enrollment":206},{"nctId":"NCT03415178","phase":"PHASE3","title":"Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-03-29","conditions":"Hypercholesterolaemia","enrollment":69},{"nctId":"NCT02938949","phase":"PHASE4","title":"Alirocumab in Patients With Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2017-01","conditions":"Myocardial Infarction, Hypercholesterolemia","enrollment":20},{"nctId":"NCT02890992","phase":"PHASE2","title":"An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-09-15","conditions":"Hypercholesterolaemia","enrollment":42},{"nctId":"NCT03750760","phase":"PHASE4","title":"Early Alirocumab to Reduce LDL-C in Myocardial Infarction","status":"WITHDRAWN","sponsor":"Imperial College London","startDate":"2020-01","conditions":"Myocardial Infarction, Dyslipidemias","enrollment":""},{"nctId":"NCT02992301","phase":"PHASE4","title":"Assessment of Atherosclerotic Plaque Characteristics Change by DCE-MRI With Alirocumab","status":"UNKNOWN","sponsor":"Westside Medical Associates of Los Angeles","startDate":"2016-11","conditions":"Atherosclerosis, Hyperlipidemia","enrollment":35},{"nctId":"NCT01663402","phase":"PHASE3","title":"ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-10","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":18924},{"nctId":"NCT02584504","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-11-30","conditions":"Hypercholesterolemia","enrollment":163},{"nctId":"NCT03552432","phase":"PHASE4","title":"The Efficacy of Alirocumab for Thin-cap fIbroatheroma in Patients With Coronary Artery Disease Estimated by Optical Coherence Tomography","status":"UNKNOWN","sponsor":"Kobe University","startDate":"2017-08-23","conditions":"Coronary Artery Disease, Thin-cap fIbroatheroma","enrollment":24},{"nctId":"NCT03014830","phase":"PHASE1","title":"Alirocumab and Reverse Cholesterol Transport","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-06-01","conditions":"Atherosclerosis, Coronary Heart Disease","enrollment":28},{"nctId":"NCT03529253","phase":"PHASE4","title":"Effect of Alirocumab(Proprotein Convertase Subtilisin/Kexin type9 Inhibitor) and Rosuvastatin or Rosuvastatin Alone on Lipid Core Plaques in Coronary Artery Disease Evaluated by Near-infrared Spectroscopy Intravascular Ultrasound","status":"UNKNOWN","sponsor":"Kobe University","startDate":"2018-04-01","conditions":"Coronary Artery Disease, Angina Pectoris","enrollment":30},{"nctId":"NCT03634293","phase":"PHASE2, PHASE3","title":"Treatment of Severe Infection With Antihyperlipidemia Drug","status":"UNKNOWN","sponsor":"Wolfson Medical Center","startDate":"2019-01","conditions":"Sepsis, Septic Shock","enrollment":712},{"nctId":"NCT02023879","phase":"PHASE3","title":"Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-12-16","conditions":"Hypercholesterolemia","enrollment":233},{"nctId":"NCT01954394","phase":"PHASE3","title":"Open Label Study of Long Term Safety Evaluation of Alirocumab","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-12-17","conditions":"Hypercholesterolemia","enrollment":986},{"nctId":"NCT03533959","phase":"","title":"To Evaluate the Efficacy of Alirocumab for Neoatherosclerosis by Using OCT, in Comparison With Standard Statin Therapy","status":"UNKNOWN","sponsor":"Kobe University","startDate":"2017-12-18","conditions":"Coronary Artery Disease Progression","enrollment":31},{"nctId":"NCT02585778","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-10-23","conditions":"Hypercholesterolaemia","enrollment":517},{"nctId":"NCT02642159","phase":"PHASE4","title":"Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-03-15","conditions":"Dyslipidemia","enrollment":413},{"nctId":"NCT02979015","phase":"PHASE1","title":"A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous (SC) Administered Alirocumab in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-11-29","conditions":"Hypercholesterolemia","enrollment":35},{"nctId":"NCT02289963","phase":"PHASE3","title":"Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-01","conditions":"Hypercholesterolemia","enrollment":199},{"nctId":"NCT01959971","phase":"PHASE1","title":"Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-12","conditions":"Hypercholesterolemia","enrollment":20},{"nctId":"NCT01926782","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2013-09","conditions":"Hypercholesterolemia","enrollment":803},{"nctId":"NCT02107898","phase":"PHASE3","title":"Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-03","conditions":"Hypercholesterolemia","enrollment":216},{"nctId":"NCT01812707","phase":"PHASE2","title":"Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in Japan","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-03","conditions":"Hypercholesterolemia","enrollment":100},{"nctId":"NCT01617655","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-06","conditions":"Hypercholesterolaemia","enrollment":107},{"nctId":"NCT01448317","phase":"PHASE1","title":"Ascending Dose Study of the Safety and Tolerability of Alirocumab (SAR236553/REGN727) in Japanese Healthy Volunteers","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-05","conditions":"Hypercholesterolemia","enrollment":32},{"nctId":"NCT01723735","phase":"PHASE1","title":"Effect of Alirocumab (SAR236553/REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-11","conditions":"Hypercholesterolemia","enrollment":79},{"nctId":"NCT01644188","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-08","conditions":"Hypercholesterolemia","enrollment":720},{"nctId":"NCT01623115","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-07","conditions":"Hypercholesterolemia","enrollment":486},{"nctId":"NCT01507831","phase":"PHASE3","title":"Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-01","conditions":"Hypercholesterolemia","enrollment":2341},{"nctId":"NCT01644474","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-07","conditions":"Hypercholesterolemia","enrollment":103},{"nctId":"NCT01644175","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-07","conditions":"Hypercholesterolemia","enrollment":316},{"nctId":"NCT01709500","phase":"PHASE3","title":"Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2012-12","conditions":"Heterozygous Familial Hypercholesterolemia","enrollment":249},{"nctId":"NCT01288443","phase":"PHASE2","title":"Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-01","conditions":"Hypercholesterolemia","enrollment":183},{"nctId":"NCT01288469","phase":"PHASE2","title":"Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-01","conditions":"Hypercholesterolemia","enrollment":92}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Praluent (Alirocumab)","genericName":"Praluent (Alirocumab)","companyName":"Federico II University","companyId":"federico-ii-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Alirocumab is a monoclonal antibody that binds to and inhibits PCSK9, a protein that degrades LDL receptors, thereby increasing LDL receptor availability and lowering blood LDL cholesterol. Used for Hypercholesterolemia (heterozygous familial and non-familial) in patients not adequately controlled by statins, Homozygous familial hypercholesterolemia, Established cardiovascular disease (secondary prevention).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}